Psoriatic Arthritis News and Research

RSS

Like rheumatoid arthritis (RA), psoriatic arthritis is a chronic inflammatory disease of the joints and connective tissue. The disease causes joint pain and swelling that can lead to crippling along with inflamed and irritated scaly red patches of skin throughout the body. It is a progressive and debilitating disease and because there are no treatments specifically approved for psoriatic arthritis, doctors often use therapies approved for RA, including nonsteroidal anti-inflammatory drugs (NSAIDs) and disease modifying anti-rheumatic drugs (DMARDs). However, no DMARDs are currently approved for use in psoriatic arthritis. There are approximately 300,000 patients with psoriatic arthritis in the United States and the disease affects both men and women most commonly between the ages 30 and 50. Psoriatic arthritis patients are generally treated by rheumatologists and dermatologists.

Methotrexate appears to facilitate bone remodeling in patients with osteoarthritis

According to new research findings presented at the 2019 ACR/ARP Annual Meeting, methotrexate did not demonstrate superior efficacy over placebo for pain relief and function evolution at three and 12 months in patients with erosive hand osteoarthritis.

11 Nov 2019

Psoriasis onset determines whether arthritis or psoriasis starts first in people with psoriatic arthritis

In a new study presented at the 2019 ACR/ARP Annual Meeting, researchers found that the age of psoriasis onset determines whether arthritis or psoriasis starts first in people with psoriatic arthritis.

11 Nov 2019

Study provides first data on infectious risk in children exposed to non-TNFi biologics and tofacitinib

A new study found that very few serious infections were seen in children born to mothers with chronic inflammatory diseases who used non-TNFi biologics or tofacitinib during pregnancy compared to children not exposed to these drugs and children exposed to TNFi biologics in utero.

10 Nov 2019

Additional medications needed to control the symptoms of juvenile idiopathic arthritis

According to new research findings presented this week at the 2019 ACR/ARP Annual Meeting, there is a profound ongoing need for additional medications to control the signs and symptoms of juvenile idiopathic arthritis, despite the availability of several approved biologic disease-modifying antirheumatic drugs (biologics).

10 Nov 2019

Study reveals safety, efficacy of live zoster vaccine for people taking TNF inhibitors

According to new research findings presented this week at the 2019 ACR/ARP Annual Meeting, the live zoster virus vaccine is safe for people who are currently receiving tumor necrosis factor inhibitor (TNFi) biologic therapies for various indications.

10 Nov 2019

Healthiest gut bacteria with plant-based or Mediterranean diet

A new study shows that specific foods that are supplied by either a plant-based or a Mediterranean-type diet can protect the gut against inflammatory disorders, by selectively promoting the growth of anti-inflammatory bacteria.

21 Oct 2019

Diagnostic value of ultrasound in comparing different types of arthritis

Ultrasound is a non-invasive and relatively inexpensive means of diagnosing a number of medical conditions. This review presents an analysis of the diagnostic value of ultrasound to draw comparison between different types of arthritic conditions.

12 Aug 2019

Finding potential treatments for autoimmune diseases

More than 50 million Americans are affected by an autoimmune disease, with women at an increased risk for developing one.

7 May 2019

ACR and Arthritis Foundation release two guidelines on juvenile idiopathic arthritis

Today, the American College of Rheumatology, in partnership with the Arthritis Foundation, released two guidelines on juvenile idiopathic arthritis.

30 Apr 2019

ACR and NPF release joint treatment guideline for psoriatic arthritis

The American College of Rheumatology and National Psoriasis Foundation have released a joint treatment guideline for psoriatic arthritis that provides evidence-based pharmacologic and non-pharmacologic recommendations on caring for treatment-naïve patients with active PsA and patients who continue to have active PsA despite treatment.

4 Dec 2018

NPF grants support advancement of psoriatic disease research

The National Psoriasis Foundation, NPF, has awarded $2.3 million in research grants and fellowships in 2018. This year's awards bring the total amount NPF has invested in the advancement of psoriatic disease research to more than $19 million.

2 Nov 2018

AbbVie’s U-ACHIEVE Phase 2b/3 dose-ranging study improves outcomes in patients with ulcerative colitis

AbbVie, a research-based global biopharmaceutical company, today announced positive results from U-ACHIEVE, an ongoing Phase 2b/3 dose-ranging study evaluating upadacitinib, an investigational JAK1-selective inhibitor, for induction and maintenance therapy in adult patients with moderately to severely active ulcerative colitis.

23 Oct 2018

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

Gilead Sciences, Inc. and Galapagos NV today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents.

22 Oct 2018

Survey: Psoriasis patients expect treatment to go beyond just clear skin and safety

Novartis, a leader in immuno-dermatology, announced today new data from a patient preference survey showing psoriasis patients want their treatment to go beyond just clear skin and safety.

12 Sep 2018

Price check on drug ads: Would revealing costs help patients control spending?

President Donald Trump wants to control spending on drugs. One of his big ideas: include prices in advertisements, just like warnings about side effects.

6 Jun 2018

FDA approves first oral medication for adults with moderately to severely active ulcerative colitis

The U.S. Food and Drug Administration today expanded the approval of Xeljanz (tofacitinib) to include adults with moderately to severely active ulcerative colitis. Xeljanz is the first oral medication approved for chronic use in this indication.

30 May 2018

Study: Psoriasis patients taking Humira show no change in aortic inflammation

An antibody used to treat the skin disease psoriasis and other chronic autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease has no effect on aortic inflammation – a key marker of future risk of major cardiovascular events – unlike other antibodies that target different aspects of the immune system.

18 May 2018

New study launched to examine effects of rheumatologic agent on bone health

Researchers at Hospital for Special Surgery have launched a pilot study to see how a drug that treats several related autoimmune disorders affects the skeleton.

7 May 2018

BWH bioengineers develop flare-responsive hydrogel to treat arthritis

Arthritis flares - the unpredictable and often sudden worsening of arthritis symptoms -- can be debilitating. These episodes can make the management of inflammatory arthritis, which includes rheumatoid arthritis and psoriatic arthritis, challenging for patients and physicians.

3 Apr 2018

New low-cost microfluidic device brings single-cell technology to bedside

Single-cell analysis holds enormous potential to study how individual cells influence disease and respond to treatment, but the lack of cost-effective and user-friendly instrumentation remains challenging.

23 Feb 2018

Psoriatic Arthritis News and Research

Further Reading

Methotrexate appears to facilitate bone remodeling in patients with osteoarthritis

Psoriasis onset determines whether arthritis or psoriasis starts first in people with psoriatic arthritis

Study provides first data on infectious risk in children exposed to non-TNFi biologics and tofacitinib

Additional medications needed to control the symptoms of juvenile idiopathic arthritis

Study reveals safety, efficacy of live zoster vaccine for people taking TNF inhibitors

Healthiest gut bacteria with plant-based or Mediterranean diet

Diagnostic value of ultrasound in comparing different types of arthritis

Finding potential treatments for autoimmune diseases

ACR and Arthritis Foundation release two guidelines on juvenile idiopathic arthritis

ACR and NPF release joint treatment guideline for psoriatic arthritis

NPF grants support advancement of psoriatic disease research

AbbVie’s U-ACHIEVE Phase 2b/3 dose-ranging study improves outcomes in patients with ulcerative colitis

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

Survey: Psoriasis patients expect treatment to go beyond just clear skin and safety

Price check on drug ads: Would revealing costs help patients control spending?

FDA approves first oral medication for adults with moderately to severely active ulcerative colitis

Study: Psoriasis patients taking Humira show no change in aortic inflammation

New study launched to examine effects of rheumatologic agent on bone health

BWH bioengineers develop flare-responsive hydrogel to treat arthritis

New low-cost microfluidic device brings single-cell technology to bedside

Michael Stryker

The past, present and future of automation and digitalization in the life sciences laboratory

Arxspan BioDrive: A Versatile Solution for Molecular Biology

Latest News